A novel therapeutic modality using CRISPR-engineered dendritic cells to treat allergies. (June 2021)

• Record Type: Journal Article
• Authors: Kim, Byoungjae; Lee, Young Eun; Yeon, Ji Woo; Go, Ga-Yeon; Byun, Junhyoung; Lee, Kijeong; Lee, Hyomin K.; Hur, Junho K.; Jang, Mihue; Kim, Tae Hoon
• Is Part Of: Biomaterials. Volume 273(2021)
• Publication Date: 2021-06
• Subjects: Dendritic cells -- CRISPR -- Vacuolar protein sorting 37 -- Adoptive cell therapies -- Allergies; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2021.120798
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Despite the important roles of dendritic cells (DCs) in airway allergies, current therapeutic strategies such as drugs, allergen immunotherapy and biologics haven't been targeted at them. In this study, we established a promising DC-based therapeutic approach for the alleviation of allergic rhinitis (AR)-associated allergic reactions, using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated targeted gene disruption. RNA sequencing analysis revealed upregulation of vacuolar protein sorting 37 B (VPS37B) in AR-derived DCs, indicating a novel molecular target. Following antigen presentation, VPS37A and VPS37B enabled endocytosis of the mannose receptor, which recognizes the house dust mite (HDM) allergen Der p 1. DCs with targeted disruption of VPS3 7 A/B alleviated Th2 cytokine production when co-cultured in vitro with allogeneic naïve CD4 + T cell from patients with AR. Furthermore, nasal administration of Vps37a/b -disrupted bone marrow DCs to a mouse model of AR resulted in strongly reduced AR-related symptoms. Thus, this novel modality using genetically engineered DCs can provide an effective therapeutic and preventative strategy for allergic diseases.